CASI Pharmaceuticals (NASDAQ:CASI) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of CASI Pharmaceuticals (NASDAQ:CASI) in a report published on Tuesday. The brokerage issued a hold rating on the biotechnology company’s stock.

CASI Pharmaceuticals Stock Down 3.3 %

CASI stock opened at $2.66 on Tuesday. CASI Pharmaceuticals has a 52 week low of $1.85 and a 52 week high of $8.48. The business has a 50-day simple moving average of $3.35 and a 200 day simple moving average of $4.90. The company has a quick ratio of 2.60, a current ratio of 3.55 and a debt-to-equity ratio of 0.78. The company has a market cap of $35.65 million, a PE ratio of -1.32 and a beta of 0.41.

CASI Pharmaceuticals (NASDAQ:CASI) last issued its earnings results on Thursday, March 28th. The biotechnology company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.05). CASI Pharmaceuticals had a negative net margin of 79.30% and a negative return on equity of 77.55%. The business had revenue of $6.03 million during the quarter, compared to analyst estimates of $9.40 million.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in CASI Pharmaceuticals stock. Howland Capital Management LLC bought a new stake in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 40,429 shares of the biotechnology company’s stock, valued at approximately $146,000. Howland Capital Management LLC owned about 0.30% of CASI Pharmaceuticals at the end of the most recent quarter. Institutional investors own 22.23% of the company’s stock.

CASI Pharmaceuticals Company Profile

CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.